The Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium, of which LLNL is part, announced the U.S. Department of Energy’s Argonne, Brookhaven and Oak Ridge national laboratories are joining the consortium to further develop ATOM’s AI-driven drug discovery platform. The public-private ATOM consortium aims to transform drug discovery from a slow, sequential and high-risk process into a rapid, integrated and patient-centric model. Founded in 2017, ATOM is developing a pre-competitive, pre-clinical drug design platform that integrates diverse data types such as physicochemical properties, in vitro assay results and anonymized human clinical data, with AI, HPC and advanced experimental technologies. The goal is to shorten the drug discovery timeline from five years to less than one year. Read more on HPCwire.